VistaGen Therapeutics, Inc. (VTGN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by VistaGen Therapeutics, Inc. on June 16, 2021. The report addresses a corporate event regarding the company's inclusion in a major market index.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses solely on a corporate governance event rather than financial performance data.
Material Changes
The primary material event reported is the announcement that VistaGen Therapeutics, Inc. expects to be added to the Russell 2000 Index. This inclusion is scheduled to take effect after the U.S. market opens on Monday, June 28, 2021, following the conclusion of the 2021 Russell Indexes annual reconstitution.
Guidance, Outlook, and Risks
Management commentary is limited to the press release attached as Exhibit 99.1, confirming the expected index addition. The filing does not contain updated financial guidance, new risk factors, contingencies, or unusual items beyond the index inclusion event.
Key Facts for Investor Verification
- Verify the effective date of the Russell 2000 Index inclusion (June 28, 2021).
- Review the attached press release (Exhibit 99.1) for any additional details on the reconstitution process.
- Confirm the company's ticker symbol (VTGN) and listing exchange (Nasdaq Capital Market).
- Note that this filing does not contain updated financial statements or operational metrics.